This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Healthcare Remove Networking Remove Pharmaceutical products Remove White Paper
article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

JANUARY 16, 2023

However, a looming risk on the horizon in 2023 is that the economic pain may produce downstream effects on global pharmaceutical supply chain networks. A worst-case scenario could also involve some pharmaceutical production in China being diverted to domestic use in early 2023. Free Report.

Pharma 64
Pharma Manufacturing Pharmaceutical Marketing 64
article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

JANUARY 16, 2023

However, a looming risk on the horizon in 2023 is that the economic pain may produce downstream effects on global pharmaceutical supply chain networks. A worst-case scenario could also involve some pharmaceutical production in China being diverted to domestic use in early 2023. Free Report.

Pharma 52
Pharma Manufacturing Pharmaceutical Marketing 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024